文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性耐受视网膜下液治疗期间视网膜下液消退而不缩短注射间隔

FLUID RESOLUTION WITHOUT SHORTENING INJECTION INTERVAL DURING SUBRETINAL FLUID-TOLERATING TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
PubMed 文献 · Retina · 2025-01-01

本回顾性研究纳入65例新生血管性年龄相关性黄斑变性患者,在接受阿柏西普治疗且黄斑中心凹受累的残余视网膜下液持续至少6个月期间,观察不缩短注射间隔情况下视网膜下液消退的发生率及相关因素。消退组中14例(43.8%)成功延长注射间隔。

要点

  • 消退组平均视网膜下液高度67.7±33.4 µm vs 未消退组109.9±44.9 µm(P<0.001)。
  • 消退组中43.8%(14/32)成功延长注射间隔。

核心结论

  • 在新生血管性年龄相关性黄斑变性耐受视网膜下液治疗期间,相当比例患者在不缩短注射间隔下出现液体消退。
  • 治疗期间残余视网膜下液较少的患者更可能实现液体消退。
  • 视网膜下液消退后,超过40%患者可延长注射间隔。

研究设计与样本

  • 回顾性研究,纳入65例新生血管性年龄相关性黄斑变性患者,均在接受阿柏西普治疗期间黄斑中心凹受累的残余视网膜下液持续至少6个月。
  • 消退组32例(维持注射间隔下视网膜下液消退),未消退组33例(研究期间视网膜下液持续存在)。

主要发现

  • 消退组平均视网膜下液高度67.7±33.4 µm vs 未消退组109.9±44.9 µm(P<0.001)。
  • 消退组最大视网膜下液高度138.3±88.6 µm vs 未消退组176.2±76.9 µm(P=0.034)。
  • 多因素分析显示平均视网膜下液高度(P=0.001)、最大视网膜下液高度(P=0.006)及抗血管内皮生长因子注射间隔(P=0.023)与视网膜下液消退显著相关。
  • 消退组中14例(43.8%)成功延长注射间隔。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the incidence and factors associated with subretinal fluid (SRF) resolution during SRF-tolerating treatment in patients with neovascular age-related macular degeneration. METHODS: This retrospective study included patients diagnosed with neovascular age-related macular degeneration who exhibited fovea-involving residual SRF persisting for at least 6 months during aflibercept treatment. Patients who showed SRF resolution despite maintaining the injection intervals were included in the resolution group, while those who exhibited persisting SRF throughout the study period were included in the nonresolution group. The incidence and associated factors of SRF resolution without reducing the injection interval were evaluated. Furthermore, the frequency of successfully extending the injection intervals while maintaining SRF resolution was identified. RESULTS: In total, 65 patients with neovascular age-related macular degeneration were included (32 and 33 in the resolution and nonresolution groups, respectively). When compared with the nonresolution group, the resolution group showed a lower mean height of SRF (67.7 ± 33.4 vs. 109.9 ± 44.9 µ m, P < 0.001) and a lower maximum height of SRF (138.3 ± 88.6 vs. 176.2 ± 76.9 µ m, P = 0.034). In multivariate analysis, the mean SRF height ( P = 0.001), maximum SRF height ( P = 0.006), and interval of anti-vascular endothelial growth factor injections ( P = 0.023) were significantly associated with the resolution of SRF. In the resolution group, 14 patients (43.8%) successfully expanded the injection interval. CONCLUSION: During SRF-tolerating treatment for neovascular age-related macular degeneration, a substantial proportion of patients exhibited resolution of fluid without shortening the injection interval. Patients with lesser residual SRF during treatment were more likely to achieve fluid resolution. After SRF resolution, injection intervals can be extended in more than 40% of patients.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Lee JH, Park SM, Kim JH, et al. FLUID RESOLUTION WITHOUT SHORTENING INJECTION INTERVAL DURING SUBRETINAL FLUID-TOLERATING TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2025. PMID: 39442014. doi:10.1097/IAE.0000000000004299

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。